Meds for rash
Pro Research Analysisby 
Searched over 200M research papers
Medications for Rash: A Comprehensive Overview
Vitamin D3 for Chemotherapy-Induced Rash
High-Dose Cholecalciferol (Vitamin D3) Recent research has highlighted the potential of high-dose cholecalciferol (vitamin D3) in mitigating severe skin reactions caused by topical chemotherapy agents. In a controlled trial, participants who received a single high dose of oral vitamin D3 showed significant reduction in acute inflammation and sustained improvement over six weeks. The study identified a specific biomarker signature that was suppressed by cholecalciferol, suggesting its role in modulating immune responses and reducing rash severity1.
Antiepileptic Drugs and Rash Incidence
Risk Factors and Incidence Rates A comprehensive review of 1,890 patients taking various antiepileptic drugs (AEDs) revealed that the incidence of drug-related rash varies significantly among different AEDs. Phenytoin, lamotrigine, and carbamazepine were associated with higher rash rates, while levetiracetam, gabapentin, and valproate had lower rates. Notably, patients with a history of rash from another AED had a significantly higher risk of developing a rash again2.
Slower Titration of Lamotrigine For patients on lamotrigine, a slower titration schedule has been shown to reduce the risk of rash. A retrospective study found that patients who followed a slower titration protocol experienced fewer rashes compared to those on a standard titration schedule. This suggests that careful dose management can mitigate the risk of lamotrigine-induced skin reactions5.
Treatments for EGFR Inhibitor-Induced Rash
Zhiyang Pingfu Liquid In a double-blinded randomized controlled trial, Zhiyang Pingfu Liquid, combined with minocycline and methylprednisolone, was effective in treating moderate to severe rashes induced by epidermal growth factor receptor inhibitors (EGFRIs). The treatment group showed a higher response rate and required a lower dosage of minocycline, indicating its potential as a complementary therapy3.
OQL025 Topical Cream A novel topical cream, OQL025, containing a prodrug that releases tofacitinib, has shown promise in preventing EGFRI-induced rashes. Preclinical studies demonstrated that the cream effectively reduced rash severity with minimal systemic exposure, making it a viable prophylactic option for patients undergoing EGFRI therapy4.
Vitamin K1 Cream Vitamin K1 cream has been evaluated for managing skin rashes during anti-EGFR monoclonal antibody treatments. Preliminary results from an observational study indicated that the cream could reduce rash severity and improve patient compliance with ongoing cancer treatments7.
Doxycycline A randomized trial assessed the efficacy of doxycycline in preventing erlotinib-induced rash in non-small-cell lung cancer patients. While doxycycline did not significantly reduce the incidence of rash, it did lower the severity of skin lesions, suggesting it may still be beneficial as part of a broader management strategy8.
Other Interventions
Topical Antihistamines Topical antihistamines, such as antazoline and diphenhydramine, are commonly used for various skin conditions, including rashes. However, their effectiveness remains questionable, and they are generally considered to have limited utility in treating skin rashes9.
Systematic Review of New Treatments A systematic review of recent interventions for EGFRI-induced rashes, excluding antibiotics and steroids, found mixed results. While some treatments like laser therapy and polydatin cream showed promise, others, such as sunscreen and adapalene gel, were less effective. This highlights the need for further research to identify reliable alternatives to traditional treatments6.
Conclusion
The management of drug-induced rashes involves a variety of strategies, from high-dose vitamin D3 for chemotherapy-induced rashes to careful titration of antiepileptic drugs and novel topical treatments for EGFRI-induced rashes. While some interventions show promise, further research is needed to establish their efficacy and safety. Understanding the specific causes and risk factors for rashes can help tailor treatments to individual patient needs, improving outcomes and quality of life.
Sources and full results
Most relevant research papers on this topic
Vitamin D3 and deconvoluting a rash
High-dose systemic cholecalciferol may effectively treat severe reactions to topical chemotherapy, potentially reducing exaggerated immune responses.
RCTComparison and predictors of rash associated with 15 antiepileptic drugs
The rate of antiepileptic drug rash is approximately five times greater in patients with another rash compared to those without, with rash rates highest with phenytoin, lamotrigine, and carbamazepine and low (1%) with several AEDs.
Observational Study
Highly CitedTopical Zhiyang Pingfu Liquid for Moderate to Severe Skin Rash Associated With EGFRIs: A double-blinded randomized controlled trial
Zhiyang Pingfu Liquid effectively improves moderate to severe EGFRIs-induced rash and reduces the use of minocycline and its side reactions.
RCT
Rigorous JournalAbstract 3211: OQL025, a topical cream for the prevention of epidermal growth factor receptor inhibitor-induced skin rash
OQL025, a topical cream containing OQRC184, effectively prevents EGFR inhibitor-induced skin rash in a rat model.
RCTSlower titration of lamotrigine reduces the risk of rash
Slower titration of lamotrigine reduces the risk of skin rash, with rash occurring in 13.3% of patients and being more severe in those with slower titration.
Observational StudyRigorous JournalThe extent to which the last decade has yielded additional treatment options for EGFR-associated rash besides classic treatment with antibiotics and corticosteroids - A systematic review.
EGFR-associated rash treatment options beyond antibiotics and steroids show mixed results, with some showing encouraging results and others potentially harmful or ineffective.
Systematic ReviewVitamin K1 cream in the management of skin rash during anti-EGFR monoclonal antibody (mAb) treatment in patients with metastatic cancer: First analysis of an observational Italian study.
Vitamin K1 cream shows a favorable impact in managing skin rash during anti-EGFR mAb treatment in metastatic cancer patients.
Observational StudyRigorous JournalDoxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trial.
Doxycycline effectively reduced the severity of erlotinib-induced folliculitis in patients with non-small-cell lung cancer, but not the incidence of rash.
RCTRigorous JournalRash promises for topical antihistamines
Topical antihistamines are promoted as remedies for stings, insect bites, sunburn, and urticarial rashes, but in 1963 we concluded they were of little use.
An inventory of medicinal products causing skin rash: Clinical and regulatory lessons
Over 90% of medicines used orally or by injection may cause skin rash as an adverse event, with the most common classes being protein kinase inhibitors, anticancer medicinal products, monoclonal antibodies, biologicals, antivirals, and retinoids.
Observational StudyRigorous Journal